Hospital
Valley Medical Facilities, INC.
Valley Medical Facilities, INC. was paid $1.86M by Medicaid between Jun 2020 and Dec 2024, across 115 billing codes. Its largest line is 99284, emergency room visit (serious) — 32% of everything it billed.
33Billing provider infoVALLEY MEDICAL FACILITIES, INC.
MC KEES ROCKS, PA 15136
MC KEES ROCKS, PA 15136
33aNPI1073598439assigned 12/08/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$1.86M
24GClaims61,199
24DCodes billed115
24AFirst – last monthJun 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#91 of 154
Median peer was paid$2.82M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 5,795 | $153K | |
| 2021 | 38,667 | $1.07M | |
| 2022 | 8,436 | $277K | |
| 2023 | 5,501 | $231K | |
| 2024incomplete | 2,800 | $124K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 32% | 4,990 | 4,824 | $587K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 4,806 | 4,657 | $381K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.1% | 925 | 891 | $150K |
| G0378 | Hospital observation service, per hour | 4.4% | 218 | 105 | $81K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 3.3% | 2,095 | 628 | $61K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.3% | 335 | 330 | $60K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.8% | 634 | 617 | $52K |
| 80053 | Comprehensive metabolic panel | 2.3% | 3,920 | 3,678 | $42K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.0% | 1,406 | 1,339 | $38K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.7% | 977 | 949 | $32K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.4% | 757 | 375 | $27K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 693 | 662 | $26K |
103 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 352 | $23K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 3,975 | $22K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.1% | 210 | $20K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 98 | $18K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 798 | $14K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 285 | $13K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 920 | $13K |
| 84703 | <1% | 1,171 | $12K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,247 | $11K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,566 | $11K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 115 | $10K |
| 80050 | General health panel | <1% | 203 | $10K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 680 | $9K |
| 11043 | <1% | 287 | $8K | |
| 80061 | Lipid panel | <1% | 463 | $6K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 291 | $6K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 238 | $6K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 238 | $6K |
| 84484 | <1% | 703 | $6K | |
| 83735 | <1% | 797 | $5K | |
| 81003 | <1% | 1,737 | $5K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 499 | $4K |
| 71045 | Radiologic examination, chest; single view | <1% | 628 | $4K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 58 | $4K |
| 83690 | <1% | 835 | $4K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 327 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 414 | $3K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 121 | $3K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,123 | $3K |
| 73610 | <1% | 146 | $3K | |
| 85730 | <1% | 424 | $2K | |
| 83605 | <1% | 356 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 321 | $2K |
| 73630 | <1% | 221 | $2K | |
| 83880 | <1% | 98 | $2K | |
| 93971 | <1% | 45 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 102 | $2K |
| 85027 | <1% | 375 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 56 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 306 | $2K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 38 | $2K |
| 85610 | <1% | 530 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 46 | $2K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 72 | $2K |
| 72100 | <1% | 84 | $2K | |
| 12001 | <1% | 14 | $2K | |
| 87040 | <1% | 96 | $2K | |
| 87186 | <1% | 223 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,960 | $1K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 24 | $1K |
| 85378 | <1% | 138 | $1K | |
| 73560 | <1% | 71 | $1K | |
| 73130 | <1% | 91 | $1K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12 | $960.30 |
| 84439 | <1% | 116 | $959.20 | |
| 80076 | <1% | 103 | $943.86 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 21 | $888.96 |
| 82803 | <1% | 40 | $823.52 | |
| 90715 | <1% | 39 | $747.58 | |
| 87077 | <1% | 130 | $732.72 | |
| 84145 | <1% | 45 | $697.34 | |
| 87070 | <1% | 152 | $627.73 | |
| 73030 | <1% | 45 | $607.20 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 14 | $560.00 |
| 76830 | Ultrasound, transvaginal | <1% | 12 | $491.90 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,359 | $476.48 |
| 82077 | <1% | 194 | $430.86 | |
| 87205 | <1% | 149 | $410.85 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 104 | $354.45 |
| 87210 | <1% | 54 | $336.04 | |
| 82607 | <1% | 27 | $309.40 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 12 | $306.81 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 495 | $293.64 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 313 | $283.52 |
| 73110 | <1% | 26 | $281.75 | |
| 82962 | <1% | 266 | $239.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 400 | $222.68 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,248 | $158.30 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 33 | $147.00 |
| 84100 | <1% | 23 | $143.48 | |
| 85651 | <1% | 42 | $117.00 | |
| 96376 | <1% | 15 | $115.44 | |
| 82043 | <1% | 12 | $104.47 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 31 | $100.60 |
| J2704 | Injection, propofol, 10 mg | <1% | 392 | $95.25 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 265 | $90.03 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 182 | $79.09 |
| 82570 | <1% | 13 | $42.91 | |
| 83550 | <1% | 12 | $30.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 436 | $24.19 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 115 | $21.31 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 23 | $4.92 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 432 | $4.20 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 28 | $3.25 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 21 | $2.36 |
| 3050F | 0% | 50 | $0.00 | |
| 3048F | 0% | 97 | $0.00 | |
| 3011F | 0% | 403 | $0.00 | |
| 3049F | 0% | 42 | $0.00 | |
| 3044F | 0% | 127 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 29 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 13 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROSENBERGER, ROBERT (CFO)
| Provider | Location | Paid |
|---|---|---|
| Adena Health System | Chillicothe, OH | $98.12M |
| Valley Medical Facilities, INC. | Sewickley, PA | $19.37M |
| Valley Medical Facilities INC | Beaver, PA | $10.29M |
| Valley Medical Facilities INC | Sewickley, PA | $4.22M |
| Valley Medical Facilities, INC. | Sewickley, PA | $3.71M |
| Valley Medical Facilities INC | Mc Kees Rocks, PA | $80K |
| Valley Medical Facilities, INC. | Wexford, PA | $32K |
| Valley Medical Facilities, INC. | Bellevue, PA | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.